ChromaDex Corporation (CDXC): Price and Financial Metrics

ChromaDex Corporation (CDXC)

Today's Latest Price: $4.83 USD

0.06 (-1.23%)

Updated Jan 26 6:55pm

Add CDXC to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 102 in Chemicals

See all "A" rated Strong Buy stocks

CDXC Stock Summary

  • For CDXC, its debt to operating expenses ratio is greater than that reported by merely 6.83% of US equities we're observing.
  • Revenue growth over the past 12 months for ChromaDex Corp comes in at 34.62%, a number that bests 85.87% of the US stocks we're tracking.
  • In terms of volatility of its share price, CDXC is more volatile than merely 7.73% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ChromaDex Corp are AEYE, NAOV, APYX, RIBT, and EKSO.
  • Visit CDXC's SEC page to see the company's official filings. To visit the company's web site, go to

CDXC Stock Price Chart Interactive Chart >

Price chart for CDXC

CDXC Price/Volume Stats

Current price $4.83 52-week high $6.00
Prev. close $4.89 52-week low $2.50
Day low $4.80 Volume 152,300
Day high $4.90 Avg. volume 281,825
50-day MA $4.92 Dividend yield N/A
200-day MA $4.78 Market Cap 298.44M

ChromaDex Corporation (CDXC) Company Bio

ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company supplies bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. The company is based inIrvine, California.

CDXC Latest News Stream

Event/Time News Detail
Loading, please wait...

CDXC Latest Social Stream

Loading social stream, please wait...

View Full CDXC Social Stream

Latest CDXC News From Around the Web

Below are the latest news stories about ChromaDex Corp that investors may wish to consider to help them evaluate CDXC as an investment opportunity.

What You Need To Know About ChromaDex Corporation's (NASDAQ:CDXC) Investor Composition

Every investor in ChromaDex Corporation ( NASDAQ:CDXC ) should be aware of the most powerful shareholder groups...

Yahoo | December 22, 2020

ChromaDex (CDXC) in Focus: Stock Moves 5.6% Higher

ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Yahoo | December 14, 2020

ChromaDex to Present at Benzinga’s Inaugural Small Cap Conference in December 2020

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the December 2020 Benzinga Small Cap Conference on Wednesday, December 9, 2020 at 11:15am ET (8:15am PT). This inaugural Small Cap Conference is a day dedicated to bridging the gap between Small Cap companies, investors and traders. The event will have multiple days of networking and education in a virtual setting. A webcast of the presentation will be posted under the investor

Business Wire | December 2, 2020

Is ChromaDex (CDXC) A Good Stock To Buy Now?

Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

Yahoo | December 2, 2020

ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a human clinical trial of Niagen® (nicotinamide riboside, or NR) investigating its potential to increase milk production among preterm mothers. This new human trial follows promising preclinical results which showed NR supplementation benefited both mother and newborn animals. The double-blinded study will compare mothers’ levels of milk production and other markers of metabolism between the experiment

Business Wire | November 17, 2020

Read More 'CDXC' Stories Here

CDXC Price Returns

1-mo -1.43%
3-mo 4.32%
6-mo -4.55%
1-year 12.06%
3-year -11.21%
5-year 21.05%
YTD 0.63%
2020 11.37%
2019 25.66%
2018 -41.67%
2017 77.64%
2016 -9.56%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9077 seconds.